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Years of sequence feature curation by UniProtKB/Swiss-Prot, PIR-PSD, NCBI-CDD, RefSeq and other database biocurators
has led to a rich repository of information on functional sites of genes and proteins. This information along with variation-
related annotation can be used to scan human short sequence reads from next-generation sequencing (NGS) pipelines for
presence of non-synonymous single-nucleotide variations (nsSNVs) that affect functional sites. This and similar workflows
are becoming more important because thousands of NGS data sets are being made available through projects such as The
Cancer Genome Atlas (TCGA), and researchers want to evaluate their biomarkers in genomic data. BioMuta, an integrated
sequence feature database, provides a framework for automated and manual curation and integration of cancer-related
sequence features so that they can be used in NGS analysis pipelines. Sequence feature information in BioMuta is collected
from the Catalogue of Somatic Mutations in Cancer (COSMIC), ClinVar, UniProtKB and through biocuration of information
available from publications. Additionally, nsSNVs identified through automated analysis of NGS data from TCGA are also
included in the database. Because of the petabytes of data and information present in NGS primary repositories, a platform
HIVE (High-performance Integrated Virtual Environment) for storing, analyzing, computing and curating NGS data and
associated metadata has been developed. Using HIVE, 31 979 nsSNVs were identified in TCGA-derived NGS data from breast
cancer patients. All variations identified through this process are stored in a Curated Short Read archive, and the nsSNVs
from the tumor samples are included in BioMuta. Currently, BioMuta has 26 cancer types with 13 896 small-scale and
308 986 large-scale study-derived variations. Integration of variation data allows identifications of novel or common
nsSNVs that can be prioritized in validation studies.
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Rapidly evolving sequencing technologies have exponen-
tially increased the output of genomics data (1, 2), which
has led to revolutionary discoveries in cancer biology and
other biological sciences (3–5). The field of biomarker dis-
covery has benefited tremendously from this technology,
with hundreds and thousands of variations being asso-
ciated with diseases from single studies (6–8). However,
there are several challenges to analyzing the vast amount
of data (Big Data) that next-generation sequencing (NGS)
technologies are creating, and all laboratories do not have
the resources to perform such large-scale studies (9, 10).
Therefore, it is not surprising that many researchers still
publish results from studies that involve less expensive gen-
otyping technologies producing smaller amounts of data.
Such smaller studies can sometimes help validate results
from larger projects, thereby providing unprecedented
levels of cooperation between scientists engaged in large-
and small-scale studies.
The forementioned cooperation is difficult because gen-
omics data are large, varied, heterogeneous and widely
distributed. Extracting and converting these data into rele-
vant information and comparing results across studies have
become an impediment for personalized genomics (11).
Additionally, because of the various computational bottle-
necks associated with the size and complexity of NGS data,
there is an urgent need in the industry for methods to
store, analyze, compute and curate genomics data. There
is also a need to integrate analysis results from large pro-
jects and individual publications with small-scale studies, so
that one can compare and contrast results from various
studies to evaluate claims about biomarkers.
Databases are mainly of two types: primary databases
that comprise raw data and secondary databases that ex-
tract relationships and filter the information available from
the primary databases and add annotations that are gen-
erated either manually or automatically. One of the prob-
lems often faced by end users of Big Data is the lack of
curated information in primary NGS data repositories,
such as NCBI Short Read Archive (12) and The Cancer
Genomics Hub (https://cghub.ucsc.edu/). It is expected that
curated secondary databases will help organize Big Data
and make it more user-friendly, similar to what secondary
databases like RefSeq (13), UniProtKB/Swiss-Prot (14) and
PIR-PSD (15) have done and are still doing for GenBank
(16). Coherent organization of analysis results of NGS
data will also allow use of higher-level databases such as
Pfam (17), PIRSFs (18), PANTHER (19), KEGG (20) and others
that group objects into functional groups and provide in-
formation on biological networks and processes.
One of the major thrusts of NGS is identification of
human genetic variations, which is used to better under-
stand human diseases (21–23). Although computational
approaches are available to predict which variants are po-
tentially deleterious and associated with disease (24–27),
the first steps involved in the process, such as mapping of
short sequence reads to human reference and identifica-
tion of single-nucleotide variations (SNVs), are computa-
tionally expensive, and few investigators have the
resources or expertise to perform analysis that involves
downloading terabytes of data from databases and pro-
cessing and computing on them (10, 28). Furthermore, vari-
ations that are associated with cancer are currently
available from diverse databases that use different work-
flows, and it is challenging to compare results from differ-
ent sources. Many of these databases and projects have
specific focus. The cBio cancer genomics portal (29) mostly
consists of data from The Cancer Genome Atlas (TCGA), and
its goal is to provide an integrated view of cancer genomics
data from TCGA and other large projects. International
Cancer Genome Consortium (ICGC) data portal allows
member institutions to manage and maintain their own
databases locally and also allows them to present data
and information to the users through a single portal (30).
UniProt provides manually curated cancer mutation data
that are available from publications (14), and resources
such as HGMD (31) have added to such data in the past
few years. The Catalogue of Somatic Mutations in Cancer
(COSMIC) (32) focuses on curating information on somatic
mutations in human cancer largely from Cancer Genome
Project at the Sanger Institute, UK, TCGA and other large-
scale published projects. Other than UniProt, to the best of
our knowledge, no group is currently engaged in extracting
data through extensive manual curation of information
available in publications and providing it freely. It is well
known that such curation is hard to perform as expounded
by Bairoch et al. in their article ‘Swiss-Prot: juggling be-
tween evolution and stability’ (33). For NGS data without
the availability of clear standards in terms of data or ana-
lysis, it is even more challenging, and it is clear that not one
group can tackle this challenge alone. There is a pressing
need to develop data and computational standards as ele-
gantly outlined in the recent Nature Genetic editorial (34).
One of the questions posed in the editorial outlines the
current state of one of the most widely used NGS pipelines
‘If I run the same sequence reads from a single cancer
genome through this pipeline of assembly and variant call-
ing twice, can I expect 70–80% concordance between the
results?’ It is clear something needs to be done, and recent
publications and efforts by the Human Genome Variation
Society show that there is a significant interest in the re-
search community to solve these problems (35).
In view of some of these difficulties, BioMuta has been
created to integrate cancer-related non-synonymous single-
nucleotide variations (nsSNVs) from various sources, which
are associated with specific cancer types and publications.
Such integration, we believe, will assist in the development
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of standards by allowing direct comparison of data pro-
vided by different groups. BioMuta is an integrated se-
quence feature database that provides a framework for
automated and manual curation of features, such as
nsSNVs. Sequence feature information in BioMuta is col-
lected not only from COSMIC (36), ClinVar (http://www.
ncbi.nlm.nih.gov/clinvar/) and UniProtKB (14) but also
through active biocuration from publications and auto-
mated analysis of NGS data from sources such as TCGA
using a novel data analysis platform HIVE (High-perform-
ance Integrated Virtual Environment) (37, 38). Although
databases such as COSMIC add large-scale data to their
databases (97 publications associated with all nsSNVs in
COSMIC), our goal is to manually curate data from small-
scale studies that, to the best of our knowledge, is not the
focus of any of the current resources other than UniProt
(118 publications associated with cancer). It is important
to note that UniProt curation effort is more comprehensive
than just curating cancer biomarkers; hence, we believe
that our work extends the UniProt effort. We believe that
computationally and manually curated and integrated data
and metadata will provide unprecedented value to biolo-
gical researchers by making available details from multiple
studies (big and small) that ordinarily a user would not be
aware of (thereby helping scientists the same way that
Model Organism Databases, RefSeq, UniProtKB/Swiss-Prot
and other curated databases have been doing for years).
Biocuration of data obtained from primary databases re-
quires a framework for analyzing, annotating and comput-
ing, which has led to the development of several curation
tools at all major bioinformatics institutes. Many of these
biocuration tools are geared toward analysis of small-scale
data such as small-number genes or proteins and therefore
are not optimal for analysis of NGS data. In an elegant
article ‘Big data: the future of biocuration’, Doug Howe
and colleagues have pointed out how curation always
lags behind data generation in funding, development and
recognition (39). The authors also provide three urgent ac-
tions to tackle this problem: (i) authors, journals and cur-
ators should work together; (ii) facilitate community-based
curation efforts; and (iii) support for scientific curation as a
professional career. We would like to add a fourth action
stating that there is an urgent need to also develop novel
platforms for biocuration of Big Data. Software and hard-
ware that have worked well for the past decades can no
longer adequately support the needs of the modern cur-
ator who is analyzing vast amounts of data. In this article,
we describe how time-tested curation of sequence features
through reading papers supplemented with data integra-
tion from diverse sources and also through the analysis of
NGS data can help create a comprehensive curated data-
base of cancer-related nsSNVs, which can be of immediate
use to the community. We subscribe to the thoughts ex-
pressed by Howe et al. that biocuration provides an
organized approach in translating the recent explosion of
biological data into meaningful results, and curated data-
bases are essential for novel discoveries in biomedical
research (39).
BioMuta data sources
Data sources for BioMuta are shown in Figure 1. Unless
otherwise noted, all accessions and identifications (IDs)
are mapped using ID Mapping table (40), followed by pair-
wise alignment and mapping of sequence positions with
methods that have been used previously (24, 41). Only
those nsSNVs that could be mapped to UniProtKB/Swiss-
Prot human protein that have the Complete Proteome key-
word tag are retained in BioMuta.
Although there are several efforts worldwide to collect
and disseminate cancer genomics variation data, it is clear
that the data are heterogeneous and it is difficult for users
to compare and contrast data from different data sources.
Different algorithms are used to identify variations, and
also, to the best of our knowledge, biocuration of variation
data from publications on cancer biomarkers is limited. In
all, 118 publications were retrieved from UniProt and 97
from COSMIC. The BioMuta project through literature
mining-assisted curation has already added 85 publications
that are not present in either COSMIC or UniProt. In add-
ition to this, the complementary Curated Short Read arch-
ive (CSR) project provides additional mutation data to
BioMuta from TCGA. Future plans include addition of
data from ICGC and other cancer genomics projects as
data linked to publications becomes available from these
resources (criteria for inclusion of external data in BioMuta
include association of record with a publication).
Catalogue of Somatic Mutations in Cancer
The file, CosmicWGS_MutantExport_v65_220513, which








Figure 1. nsSNV data from various sources are collected, fil-
tered and mapped to UniProtKB/Swiss-prot–defined complete
human proteome and integrated into BioMuta.
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from COSMIC (42). The first step involved filtering out
entries without a PubMed identification (PMID). Because
the cancer descriptions in COSMIC are complex, the
cancer description columns (primary site, site subtype, pri-
mary histology and histology subtype) were manually
checked and converted into TCGA cancer categories
(https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). A total
of 283 895 nsSNVs of 904 143 variations were retrieved
from the COSMIC file.
ClinVar
ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) is a database
that provides information about sequence variations and
associations to human health. Tables were downloaded
from the ClinVar ftp site (ftp://ftp.ncbi.nlm.nih.gov/pub/
clinvar/). A total of 4590 cancer-related variations with
PMIDs were retained. The majority of the records from
ClinVar were filtered out because they either did not
have PMID or the cancer type was not easily discernible.
UniProtKB
UniProt (14) provides comprehensive curated protein se-
quences and functional information. All proteins that con-
tained cancer-related keywords (cancer, carcinoma glioma,
blastoma, leukemia, melanoma, adenocarcinoma, lymphoma
and tumor) in the sequence feature (FT) line were extracted
from UniProtKB/Swiss-Prot–defined human complete prote-
ome, and 2279 manually verified variations were added to
BioMuta. UniProt does not provide genomic location; hence,
for these variations genomic locations are not provided.
Manual curation
By using key terms [cancer, single-nucleotide polymorphism
(SNP), biomarker, variant, variation, etc.], articles from
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) were
retrieved and manually curated to obtain variation infor-
mation. PMIDs not present at the time of curation in
COSMIC, ClinVar and UniProtKB were selected for manual
curation. A total of 139 sites from 85 articles were added to
BioMuta through this process.
Curated Short Read archive
Currently there are thousands of large-scale NGS data from
patients and cell line samples that are available from pri-
mary short read data repositories such as TCGA (http://can
cergenome.nih.gov/) and NCBI Short Read Archive (43) and
listed through dbGaP (44). We expect that integrated ana-
lysis of these data will lead to novel discoveries. For ex-
ample, NGS data from TCGA provides a rich source of
sequence data that can be mined to extend and comple-
ment mutation and SNV information available from dbSNP,
UniProt, COSMIC and other variation databases. We intend
to identify all nsSNVs from representative samples from all
data sets that have matched case and controls and also
have exome and RNA-Seq data. Analysis of these subsets
of samples provides a rich source for biological discovery.
All variation data can be further analyzed using SNVDis,
which is a proteome-wide SNV distribution analysis tool
(24). For this study, NGS data from 20 breast cancer patients
(22 tumor samples and 33 normal) were analyzed to iden-
tify nsSNVs. Results from this analysis and additional infor-
mation such as phenotypic information were curated and
added to a CSR. A total of 31 979 nsSNVs of 291 803 SNVs
from tumor samples were added to BioMuta. Direct access
to CSR is available at http://hive.biochemistry.gwu.edu/dna.
cgi?cmd=csr. Users can search for variations present in
tumor and normal samples using gene or protein accession
numbers and view whether the variation is already present
in dbSNP. Searching using TCGA IDs is also supported. The
CSR curation platform is supported by HIVE, which is
described in the section below.
HIVE for biocuration
A sophisticated IT framework is required for analyzing,
annotating and computing the vast amounts of data
generated using NGS technologies. HIVE provides such a
platform and is used to analyze NGS data. HIVE is a bio-
computing operating system, which provides the ideal
backbone to integrate modular software into a data analy-
tics backbone. The HIVE architecture provides a highly par-
allel processing environment, which allows optimal
compatibility and performance for both native and indus-
try-standard tools. All algorithmic services and tools manip-
ulate data from three sources: data loaded preliminary into
the system, data provided by the user during a computa-
tion inquiry or data computed during a previous computa-
tion. HIVE has an ensemble of parsers, loaders, converters
and validators for all industry-standard biological data for-
mats (such as sequences, alignments, profiles). All data in
the system are available for downloading in a variety of
industry-accepted data formats (fasta, SFF, fastq, BAM,
SAM). The primary step in many genomic workflows is to
align and map short reads to a reference genome. There
are several software programs with their own alignment
algorithms. The different algorithmic approaches of each
tool create computational trade-offs in speed, accuracy
and performance to optimize the detection of variants in
the alignment (45, 46). Currently, HIVE has the following
alignment tools integrated and parallelized: HIVE-hexagon
(native HIVE alignment tool), Bowtie (47) and BWA (48).
After alignment of short reads to a reference genome
with any of the alignment tools, variants can be identified
through comparison of the sample genome with the refer-
ence genome.
Currently, the following protocol is in use in the CSR pro-
ject (a BioMuta data source) to identify variations: Short read
data are obtained from TCGA (http://cancergenome.nih.gov/)
via The Cancer Genomics Hub data portal (https://cghub.ucsc.
.............................................................................................................................................................................................................................................................................................
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edu/). The reference used in the alignment is the hg19,
GRCh37 Genome Reference Consortium Human Reference
37 (GCA_000001405.1) downloaded from UCSC (http://
hgdownload.cse.ucsc.edu/goldenPath/hg19/chromosomes/).
UniProtKB protein amino acid position and ID mapping is
done using SNVDis and ID Mapping services (24, 40). After
the raw SNV data are generated using Bowtie (47) and SAM
tools (49), filters are used to select high-quality SNVs that are
of desirable coverage (>10 reads) and quality score (>20).
The filtration process also rejects detected SNVs falling out of
the exome regions. Results of the variation profiling tool can
be further evaluated manually using HIVE native displays as
shown in Figure 2.
BioMuta content
To ensure usability of the database, care is taken to verify
that all SNVs in BioMuta have the following characteristics:
(i) has PMID for all imported data, (ii) is an nsSNV, (iii) can
be mapped to UniProtKB/Swiss-Prot–defined human
proteome and (iv) has either gene/protein or genome coor-
dinates. SNVs associated with PMIDs that report <1000 var-
iations are considered small-scale study variations, and
those that are associated with PMIDs that report >1000
variations are considered large-scale studies and are
hence marked as large-scale study variation. Literature
mining variations are those that are automatically
extracted through literature mining procedures. Such var-
iations are currently not available to the public. Table 1
provides detailed statistics of the number of variations
obtained from different databases. The majority of the var-
iations are obtained from COSMIC and CSR-TCGA. Through
manual curation of 85 publications, 139 sites were added to
BioMuta. Adding such manually curated records in BioMuta
is one of the top priorities of the project. Table 2 provides
an overview of example search parameters, number of
Figure 2. HIVE interface showing result obtained from SNV profiling of short sequence reads mapped to nucleotide sequence
surrounding a variation site. (A) Overall coverage result with the 121 485 241 position, showing variation. (B) Reads mapped to
the reference sequence with the column of interest are highlighted in yellow. (C) Only variations are shown in this panel.
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articles retrieved and overall number of articles that were
found to include variation information that can be included
in BioMuta. More specifically, different combinations of
search terms are used and multiple search results are com-
bined to create a nonredundant set of PMIDs. Title and
abstracts are read to extract articles of interest. Titles/
abstracts with gene/protein name, cancer type, tumor
type, variation site, mutation- and biomarker-related
words are prioritized for curation. The next step involves
reading the manuscript and any relevant Supplementary
Tables to retrieve variation-related information. Finally,
accession numbers, mutation and mutation positions are
verified, and attempts are made to manually check and
include missing information such as chromosomal location,
Table 1. Twenty-six cancer types and 322 882 (small-scale: 13 896; large-scale: 308 986) associated variations in BioMuta





















Lung (LUAD) 121 80 006 105
Colon (COAD) 486 68 249 235 20
Breast (BRCA) 176 7386 342 1 3314 16 31979
Esophageal (ESCA) 43 25 980 1
Ovarian (OV) 1229 16 411 31 1276 4
Skin (SKCM) 496 17 041 2
Prostate (PRAD) 77 10 920 1
Head and neck (HNSC) 716 11 838 1
Rectum (READ) 9760 10
Lymphoid (DLBC) 1710 7006
Adrenocortical (ACC) 1000 4515 1
Pancreatic (PAAD) 896 3164 3
Brain (LGG) 773 2383
Uterine (UCEC) 490 1414 1
Kidney (KIRC) 893 115
Liver (LIHC) 1224 1023 14 3
Glioblastoma (GBM) 776
Acute myeloid (LAML) 409 8
Thyroid (THCA) 513 7 3
Bladder (BLCA) 450 2
Lung (LUSC) 256
Stomach (STAD) 89
Kidney renal (KIRP) 33 42
Kidney chromo (KICH) 57
Non-small lung (NSCLC) 4 8
Cervical (CESC) 1 5
Otherd 5319
aLUAD, lung adenocarcinoma; COAD, colon adenocarcinoma; BRCA, breast invasive carcinoma; ESCA, esophageal carcinoma; OV, ovarian
serous cystadenocarcinoma; SKCM, skin cutaneous melanoma; PRAD, prostate adenocarcinoma; HNSC, head and neck squamous cell
carcinoma; READ, rectum adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ACC, adrenocortical carcinoma;
PAAD, pancreatic adenocarcinoma; LGG, brain lower grade glioma; UCEC, uterine corpus endometrial carcinoma; KIRC, kidney renal clear
cell carcinoma; LIHC, liver hepatocellular carcinoma; GBM, glioblastoma multiforme; LAML, acute myeloid leukemia; THCA, thyroid
carcinoma; BLCA, bladder urothelial carcinoma; LUSC, lung squamous cell carcinoma; STAD, stomach adenocarcinoma; KIRP, kidney
renal papillary cell carcinoma; KICH, kidney chromophobe; NSCLC, non-small cell lung cancer; CESC, cervical squamous cell carcinoma
and endocervical adenocarcinoma.
bSmall-scale—SNVs associated with publications that report <1000 SNVs.
cLarge-scale—SNVs associated with publications that report >1000 SNVs or SNVs identified using computational pipelines from existing
NGS data.
dCancer types not specified or well defined.
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accession number/s and valid HGNC gene symbols. Curation
results are cross-checked by curators and through the vali-
dation process.
Users can download the entire BioMuta table or browse
the database by searching for records using gene names
and UniProtKB or RefSeq accessions. Search results include
a graphical representation of the mutations and a table
that can be downloaded in tab-delimited format and
further analyzed by Microsoft Excel or simple scripts.
Users have the ability to select a specific row in the results
table and send comments to BioMuta curators. This type of
direct feedback will help us improve database content. All
records are linked to the Early Detection Research Network
(EDRN) Knowledge Environment through its online public
portal (50). EDRN is a distributed knowledge network that
integrates cancer biomarker research results from across
the network. This includes the integration of annotations
regarding biomarkers under study with the results from
those studies that can be used for analysis. The biomarkers
themselves are annotated from studies performed by the
EDRN and linked to the publications and external protein
and genomic databases. The annotations include informa-
tion about the success of the biomarkers that have been
studied. The EDRN Knowledge Environment allows for
external linking to the specific data captured within the
system. This has allowed for BioMuta and EDRN to be
linked together through specific attributes of the biomar-
kers, including common gene names provided by HGNC
(51), which are annotated with the biomarkers within the
EDRN knowledge system and biomarker database. The inte-
gration of these highly curated systems becomes plausible
given the adoption of common identifiers and the promo-
tion of online portals and web services.
BioMuta has data from various sources, and it is possible
that some of these databases might contain errors in terms
of the genomic coordinates and/or the gene/protein
positions. To reduce the propagation of these types of
errors, we have validation procedures to check the table.
To address the heterogeneity of the different variation
data sources, all variant records are unified via the
UniProtKB/Swiss-Prot human proteome set by providing
each variant a UniProtKB accession number and position.
To achieve this, all variations with genomic coordinates are
first mapped to genes/transcripts using SeattleSeq services
(http://snp.gs.washington.edu/SeattleSeqAnnotation137)
and then mapped to UniProtKB protein accession and posi-
tion using methods described previously (24). Briefly, the
mapping process includes mapping of RefSeq accessions to
UniProtKB accessions using ID mapping services provided by
Protein Information Resource and UniProt (40), followed by
pairwise alignment of the sequences to map the positions.
For all the records that cannot be correctly mapped to the
coding region or if the amino acid does not match the
UniProtKB-defined proteome or for nucleotides if they do
not match the RefSeq nucleotide for that position, the
entire row is discarded after manual evaluation of the error.
BioMuta utility
One of the immediate applications of the BioMuta project is
to evaluate variations that are obtained from various sources
through biocuration and thereby provide ways to prioritize
variations for further experimental evaluation by the EDRN
community and others. The evaluations can be performed by
both comparing and contrasting mutations data from differ-
ent cancer types and/or from different studies. Additional
evaluation of mutations can also be performed by interro-
gating NGS data from TCGA or ICGC or other projects to see
whether specific mutations are present in certain cancer
types and what their frequency is (Figure 3).
One of the goals of researchers is assessing the func-
tional impact of variations. Figure 4a provides example ana-
lysis results of how the BioMuta data can be used to better
understand the functional impact of nsSNVs from different
cancer types. For this analysis, all the nsSNVs were mapped
to functional sites that were obtained from UniProtKB
sequence feature annotation. Based on this analysis, we
notice that a large number of posttranslational modifica-
tions (PTMs) and active and binding sites are affected by
nsSNVs. It is interesting to note that for breast cancer, there
is a high number of nsSNVs that affect N-linked glycosyla-
tion sites. To find out whether certain types of PTM or
other functional sites are resistant to variations, P-values
were calculated based on methods described earlier (24,
52), to estimate the significance between observed and
expected numbers. The results indicate, as expected, for
several of the functional sites, observed variations are sig-
nificantly lower than the calculated expected values. More
specifically—acetylation: observed 105, expected 224.28,
P-value 4.53E-19; active site: observed 59, expected 93.18,









Polymorphism, biomarker, cancer 5215 20
SNP, exon, cancer 394 16
Gene namec, cancer, SNP 20 4
Total 143d
aTotal number of articles retrieved using the search terms.
bArticles from which data were extracted for inclusion in BioMuta.
cTargeted curation of specific genes, e.g. MTA1, MTA2, SULF2,
SHBG, DLX4, etc.
dArticles and annotations that pass validation step are retained.
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P-value 9.89E-05; binding site: observed 102, expected
123.69; C-linked glycosylation: observed 1, expected 1.68;
g-carboxyglutamic acid: observed 5, expected 2.61;
methylation: observed 45, expected 26.09, P-value 2.42E-
07; N-linked glycosylation: observed 551, expected 467.78,
P-value 9.60E-05; O-linked glycosylation: observed 28,
expected 76.64, P-value 1.54E-10; palmitoylation: observed
1, expected 4.52; phosphorylation: observed 1083, expected
2325.07, P-value 1.71E-183; prenylation: observed 0,
expected 2.00; S-nitrosylation: observed 7, expected 22.25,
P-value 1.65E-04; sulfation: observed 1, expected 1.68;
sumoylation: observed 7, expected 19.19, P-value 1.33E-
03; ubiquitylation: observed 257, expected 668.12, P-value
3.78E-74 (P-values >0.05 are not shown). Data from specific
cancer types were also analyzed to evaluate whether cer-
tain PTMs are more affected by certain types of cancer
(Figure 4b). The majority of functional sites analyzed
seem to be protected from mutation (significantly less
observed variations than expected). It is hard to explain
why for certain cancer types some of the functional sites
appear to be less protected. More data are required to
evaluate these trends. All the variations obtained in our
pipeline are also integrated into SNVDis (24). To facilitate
evaluation of the effects of variations, PolyPhen-based (6)
predictions are also included in the BioMuta table. SNVDis
provides users with applications that can be used to evalu-
ate the distribution of nsSNVs on protein functional sites,
domains and pathways at the entire proteome level. Such
proteome-wide analysis is complementary to functional
impact analysis using methods such as PolyPhen (27) and
SIFT, (26) and similar algorithms.
Integration of data, as the one performed in this study,
allows identification of genes that have high level of varia-
tions. From the small-scale category, the top five genes in
terms of number of unique nsNSVs–PMID pairs are TP53,
PBRM1, MEN1, ARID1A and NF1. For the large-scale cate-
gory, the genes are BRCA2, BRCA1, TP53, TTN and
CACNA1C. In search of variants that are recorded in more
than one database, the variants that have same UniProtKB
accession, amino acid position and variation were identified.
There are 518 variants found in two or more data sources
(Supplementary Table S1). We expect this overlap to
increase as more data from other cancer-genomics studies
are included. Of these 518 overlapping variants, the CSR
database contributes the most to this number of shared var-
iants (>95%), thereby showcasing the utility of evaluating
variations by analyzing TCGA data. Another interesting fact








































Phase II: Future plans
*Variaons  associated with 
mulple cancer types can be viewed
Figure 3. BioMuta data flow and utility in evaluating variations obtained from various cancers.
.............................................................................................................................................................................................................................................................................................
Page 8 of 11












manually curated variation overlaps are from CSR and not
from COSMIC, suggesting that CSR database even with a
limited number of patient data might already be useful in
evaluating published cancer-related variations.
Our overarching goal is to provide whole-genome and
exome analysis capabilities through HIVE or similar
platforms where users can upload short read sequences
and map them to the human reference genome followed
by flagging of sites that are impacted by variations and are
already reported by other studies. Such analysis will allow
researchers to quickly evaluate personal genomes of








































































Figure 4. Loss of functional sites (PTM sites, active and binding sites). (A) Top six cancer types with the highest number of records
in BioMuta. Lung adenocarcinoma (LUAD), colon adenocarcinoma (COAD), breast invasive carcinoma (BRCA), esophageal carci-
noma (ESCA), ovarian serous cystadenocarcinoma (OV) and skin cutaneous melanoma (SKCM). (B) Statistical analysis of loss of
functional sites show that for some cancer type–specific functional sites are less susceptible to variation (colored graph area
almost touching the perimeter—where perimeter represents P-value close to 0).
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Efforts directed toward creating databases such as CSR,
ClinVar, RefSeq, UniProt, HGMD (31) PharmGKB 54),
IntOGen (7), ICGC (8) and others, which provide informa-
tion on variations and disease or other phenotypic details,
will provide methods connecting genomic alterations with
clinical parameters. These efforts are vital for using the full
potential of NGS technologies (3), leading to novel discov-
eries that will translate to diagnostic and therapeutic tar-
gets (4, 54). All of these databases will benefit from
additional variation sites extracted through the biocuration
of information from publications. Our future plans include
automated literature mining methods that will provide tar-
geted extraction of publications that can be used to anno-
tate major cancer genes. We also intend to provide
community annotation tools to cancer biologists so that
they can add notes related to experimental validation of
the variations and the possibility of using them as diagnos-
tic or prognostics markers. This information can be used by
curators to provide additional structured information to
these entries. Engaging the entire scientific community in
community annotation efforts has been difficult (51, 55).
Therefore, we will initially focus on involving the EDRN
community and other specific cancer researcher groups
such as Alliance of Glycobiologists (http://glycomics.cancer.
gov/) in our initial community annotation efforts.
Access
BioMuta and CSR are updated at least once every 4 months.
Access to all data is available without any login require-
ments. To use HIVE’s computationally intensive tools, users
need to register at http://hive.biochemistry.gwu.edu/dna.
cgi?cmd=userReg. Temporary login is provided for evalua-
tion purposes such as browsing the interfaces or viewing
example analysis results. HIVE login URL: http://hive.biochem-
istry.gwu.edu/dna.cgi?cmd=login&follow=home; evaluation
userid: xlhive@yahoo.com; password: pilotHive5. Users can
also install HIVE on their own hardware or use HIVE-in-a-
box, which is a low-cost alternative to analyze NGS data
using predetermined workflows. For additional details,
users are encouraged to contact the HIVE team (http://hive.
biochemistry.gwu.edu/dna.cgi?cmd=contact).
Supplementary Data
Supplementary data are available at Database Online.
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